Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Named profile Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted TherapyRepresentative category illustration – no product packaging is shown.Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted Therapy
Palladia is an FDA-approved prescription veterinary tyrosine kinase inhibitor for treatment of Patnaik grade II or III recurrent canine cutaneous mast cell tumors, with or without regional lymph-node…
Read more
Named profile Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine LymphomaRepresentative category illustration – no product packaging is shown.Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine Lymphoma
Verdinexor is an oral prescription antineoplastic for certain dogs with lymphoma. FDA announced full approval in January 2026 after the product's earlier conditional-approval pathway; publication should use the…
Read more
Named profile K9 Immunity Plus Soft Chews: Product ProfileRepresentative category illustration – no product packaging is shown.K9 Immunity Plus Soft Chews: Product Profile
K9 Immunity Plus is a named branded product for Dogs; manufacturer positioning must be kept separate from independent clinical evidence.
Read more
Named profile Vicano Support Life Tabs: Product ProfileRepresentative category illustration – no product packaging is shown.Vicano Support Life Tabs: Product Profile
Vicano Support Life Tabs is a named branded product for Dogs; manufacturer positioning must be kept separate from independent clinical evidence.
Read more
Named profile Canalevia-CA1 (Crofelemer): Chemotherapy-Induced Diarrhoea SupportRepresentative category illustration – no product packaging is shown.Canalevia-CA1 (Crofelemer): Chemotherapy-Induced Diarrhoea Support
crofelemer delayed-release tablets is covered as prescription antisecretory gastrointestinal medicine; supportive care, not antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Mitotane in Canine Adrenal Disease and Adrenocortical TumoursRepresentative category illustration – no product packaging is shown.Mitotane in Canine Adrenal Disease and Adrenocortical Tumours
mitotane (o,p′-DDD) is covered as adrenocorticolytic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Mesna in Veterinary Oncology: Uroprotection With Ifosfamide and CyclophosphamideRepresentative category illustration – no product packaging is shown.Mesna in Veterinary Oncology: Uroprotection With Ifosfamide and Cyclophosphamide
mesna (sodium 2-mercaptoethane sulfonate) is covered as protocol-linked uroprotective medicine; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Furosemide as a Cyclophosphamide Uroprotection Adjunct in DogsRepresentative category illustration – no product packaging is shown.Furosemide as a Cyclophosphamide Uroprotection Adjunct in Dogs
furosemide used as a protocol adjunct is covered as loop diuretic used within selected canine cyclophosphamide protocols; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring…
Read more
Named profile H1 and H2 Blockade Around Mast-Cell Degranulation RiskRepresentative category illustration – no product packaging is shown.H1 and H2 Blockade Around Mast-Cell Degranulation Risk
H1-receptor and H2-receptor blocking companion medicines is covered as protocol-linked supportive medicines; not direct antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led…
Read more
Named profile MOPP and LOPP for Canine Lymphoma: Distinct Alkylator-Rich ProtocolsRepresentative category illustration – no product packaging is shown.MOPP and LOPP for Canine Lymphoma: Distinct Alkylator-Rich Protocols
MOPP and LOPP multi-agent chemotherapy is covered as alkylator-rich canine lymphoma protocols, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Melphalan and Prednisone or Prednisolone for Canine Multiple MyelomaRepresentative category illustration – no product packaging is shown.Melphalan and Prednisone or Prednisolone for Canine Multiple Myeloma
melphalan with prednisone or prednisolone is covered as oral alkylator-based protocol for canine multiple myeloma, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Vinblastine and Prednisone or Prednisolone for Canine Mast Cell TumoursRepresentative category illustration – no product packaging is shown.Vinblastine and Prednisone or Prednisolone for Canine Mast Cell Tumours
vinblastine with prednisone or prednisolone is covered as combination chemotherapy for selected canine mast-cell tumours, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more